Transcriptome of hypertension-induced left ventricular hypertrophy and its regression by antihypertensive therapies

Hypertension Research

Volumn 32, Issue 5, 2009, Pages 347-357

  Gallego Delgado, Julio ^a,d   Connolly, Susan B ^b,c   Lázaro, Alberto ^a,d   Sadlier, Denise ^b,c   Kieran, Niamh E ^b,c   Sugrue, Declan D ^b,c   Doran, Peter ^b   Brady, Hugh R ^b   Osende, Julio ^a   Egido, Jesus ^d  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c Dublin Molecular Medicine Centre   (Ireland)

^d UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DOXAZOSIN; LOSARTAN; QUINAPRIL; TRANSCRIPTOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL FUNCTION; CELL GROWTH; CELL METABOLISM; CELL PROLIFERATION; CLUSTER ANALYSIS; CONTROLLED STUDY; CYTOSKELETON; DOWN REGULATION; DRUG RESPONSE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE SEQUENCE; GENETIC LINKAGE; GENETIC TRANSCRIPTION; HEART CONTRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HYPERTENSION; MALE; MICROARRAY ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; RAT; REMISSION; SIGNAL TRANSDUCTION; SPONTANEOUSLY HYPERTENSIVE RAT; THERAPY EFFECT; TREATMENT DURATION; UNINDEXED SEQUENCE; UPREGULATION; WISTAR KYOTO RAT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; DOXAZOSIN; DRUG THERAPY, COMBINATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LOSARTAN; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RATS; RATS, INBRED SHR; RATS, INBRED WKY; TETRAHYDROISOQUINOLINES;

EID: 68249136991     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2009.27     Document Type: Article

References (55)

1. Levy D. Left ventricular hypertrophy. Epidemiological insights from the Framingham Heart Study. Drugs 1988; 35(Suppl 5): 1-5.
2. Mosterd A, Cost B, Hoes AW, de Bruijne MC, Deckers JW, Hofman A, Grobbee DE. The prognosis of heart failure in the general population: The Rotterdam Study. Eur Heart J 2001; 22: 1318-1327.
3. Depre C, Shipley GL, Chen W, Han Q, Doenst T, Moore ML, Stepkowski S, Davies PJ, Taegtmeyer H. Unloaded heart in vivo replicates fetal gene expression of cardiac hypertrophy. Nat Med 1998; 4: 1269-1275.
4. Lips DJ, deWindt LI, van Kraaij DJ, Doevendans PA. Molecular determinants of myocardial hypertrophy and failure: Alternative pathways for beneficial and maladaptive hypertrophy. Eur Heart J 2003; 24: 883-896.
5. Lin J, Davis HB, Dai Q, Chou YM, Craig T, Hinojosa-Laborde C, Lindsey ML. Effects of early and late chronic pressure overload on extracellular matrix remodeling. Hypertens Res 2008; 31: 1225-1231.
6. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nienninen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Wedel H, Lindholm LH, Dahlöf B:, LIFE Study Investigators. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004; 292: 2343-2349.
7. Wing LM, Reid CM, Ryan P, Beilin LI, Brown MA, Jennings GL, Johnston Cl, McNeil JJ, Macdonald GJ, Marley JE, Morgan TO, West MJ;, Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348: 583-592.
8. Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Suzuki Y, Mezzano S, Plaza JJ, Egido J. Role of the renin-angiotensin system in vascular diseases: Expanding the field. Hypertension 2001; 38: 1382-1387.
9. Kieran NE, Doran PP, Connolly SB, Greenan MC, Higgins DF, Leonard M, Godson C, Taylor CT, Henger A, Kretzler M, Burne MJ, Rabb H, Brady HR. Modification of the transcriptomic response to renal ischemia/ reperfusion injury by lipoxin analog. Kidney Int 2003; 64; 480-492.
10. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998; 95: 14863-14868.
11. Fellenberg K, Hauser NC, Brors B, Neutzner A, Hoheisel JD, Vingron M. Correspondence analysis applied to microarray data. Proc Natl Acad Sci USA 2001; 98: 10781-10786.
12. Draghici S, Khatri P, Bhavsar P, Shah A, Krawetz SA, Tainsky MA. Onto-Tools, the toolkit of the modern biologist: Onto-Express, Onto-Compare, Onto-Design and Onto-Translate. Nucleic Acids Res 2003; 31: 3775-3781.
13. Huss JM, Kelly DP. Mitochondrial energy metabolism in heart failure: A question of balance. J Clin Invest 2005; 115: 547-555.
14. Gallego-Delgado J, Lazaro A, Osende JI, Barderas MG, Duran MC, Vivanco F, Egido J. Comparison of the protein profile of established and regressed hypertension-induced left ventricular hypertrophy. J Proteome Res 2006; 5: 404-413.
15. Lehman JJ, Kelly DP. Gene regulatory mechanisms governing energy metabolism during cardiac hypertrophic growth. Heart Fail Rev 2002; 7: 175-185.
16. van der Lee KA, Vork MM, De Vries JE, Willemsen PH, Glatz JF, Reneman RS, Van der Vusse GJ, Van Bilsen M. Long-chain fatty acid-induced changes in gene expression in neonatal cardiac myocytes. J Lipid Res 2000; 41: 41-47.
17. Masuzaki H, Jingami H, Matsuoka N, Nakagawa D, Ogawa Y, Mizuno M, Yoshimasa Y, Yamamoto T, Nakao K. Regulation of very-low-density lipoprotein receptor in hypertrophic rat heart. Circ Res 1996; 78: 8-14.
18. Stanley WC, Morgan EE, Huang H, McElfresh TA, Sterk JP, Okere IC, Chandler MP, Cheng J, Dyck JR, Lopaschuk GD. Malonyl-CoA decarboxylase inhibition suppresses fatty acid oxidation and reduces lactate production during demand-induced ischemia. Am J Physiol Heart Circ Physiol 2005; 289: H2304-H2309.
19. Lydell CP, Chan A, Wambolt RB, Sambandam N, Parsons H, Bondy GP, Rodrigues B, Popov KM, Harris RA, Brownsey RW, Allard MF. Pyruvate dehydrogenase and the regulation of glucose oxidation in hypertrophied rat hearts. Cardiovasc Res 2002; 53: 841-851.
20. Taegtmeyer H, Razeghi P, Young ME. Mitochondrial proteins in hypertrophy and atrophy: A transcript analysis in rat heart. Clin Exp Pharmacol Physiol 2002; 29: 346-350.
21. Leong HS, Brownsey RW, Kulpa JE, Allard MF. Glycolysis and pyruvate oxidation in cardiac hypertrophy - why so unbalanced? Comp Biochem Physiol A Mol Integr Physiol 2003; 135: 499-513.
22. Sambandam N, Lopaschuk GD, Brownsey RW, Allard MF. Energy metabolism in the hypertrophied heart. Heart Fail Rev 2002; 7: 161-173.
23. Sano M, Fukuda K, Kodama H, Pan J, Saito M, Matsuzaki J, Takahashi T, Makino S, Kato T, Ogawa S. Interleukin-6 family of cytokines mediate angiotensin II-induced cardiac hypertrophy in rodent cardiomyocytes. J Biol Chem 2000; 275: 29717-29723.
24. Uozumi H, Hiroi Y, Zou Y, Takimoto E, Toko H, Niu P, Shimoyama M, Yazaki Y, Nagai R, Komuro I. gp130 plays a critical role in pressure overload-induced cardiac hypertrophy. J Biol Chem 2001; 276: 23115-23119.
25. Fujio Y, Nguyen T, Wencker D, Kitsis RN, Walsh K. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation 2000; 101: 660-667.
26. Condorelli G, Drusco A, Stassi G, Bellacosa A, Roncarati R, Iaccarino G, Russo MA, Gu Y, Dalton N, Chung C, Latronico MV, Napoli C, Sadoshima J, Croce CM, Ross Jr J. Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc Natl Acad Sci USA 2002; 99: 12333-12338.
27. Shioi T, McMullen JR, Kang PM, Douglas PS, Obata T, Franke TF, Cantley LC, Izumo S. Akt/protein kinase B promotes organ growth in transgenic mice. Mol Cell Biol 2002; 22:2799-2809.
28. Matsui T, Li L, Wu JC, Nagoshi T, Picard MH, Liao R, Rosenzweig A. Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J Biol Chem 2002; 277: 22896-22901.
29. Tomita Y, Kusama Y, Seino Y, Munakata K, Kishida H, Hayakawa H. Increased accumulation of acidic fibroblast growth factor in left ventricular myocytes of patients with idiopathic cardiomyopathy. Am Heart J 1997; 134: 779-786.
30. Fernandez B, Buehler A, Wolfram S, Kostin S, Espanion G, Franz WM, Niemann H, Doevendans PA, Schaper W, Zimmermann R. Transgenic myocardial overexpression of fibroblast growth factor-1 increases coronary artery density and branching. Circ Res 2000; 87: 207-213.
31. Chen H, Huang XN, Stewart AF, Sepulveda JL. Gene expression changes associated with fibronectin-induced cardiac myocyte hypertrophy. Physiol Genomics 2004; 18: 273-283.
32. Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. FASEB J 2004; 18: 816-827.
33. Hayata N, Fujio Y, Yamamoto Y, Iwakura T, Obana M, Takai M, Mohri T, Nonen S, Maeda M, Azuma J. Connective tissue growth factor induces cardiac hypertrophy through Akt signaling. Biochem Biophys Res Commun 2008; 370: 274-278.
34. Rosenkranz S. TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res 2004; 63: 423-432.
35. Che ZQ, Gao PJ, Shen WL, Fan CL, Liu JJ, Zhu DL, Angiotensin II-stimulated collagen synthesis in aortic adventitial fibroblasts is mediated by connective tissue growth factor. Hypertens Res 2008; 31: 1233-1240.
36. Tsutsui H, Matsushima S, Kinugawa S, Ide T, Inoue N, Ohta Y, Yokota T, Hamaguchi S, Sunagawa K. Angiotensin II type 1 receptor blocker attenuates myocardial remodeling and preserves diastolic function in diabetic heart. Hypertens Res 2007; 30: 439-449.
37. Yoshioka J, Schulze PC, Cupesi M, Sylvan JD, MacGillivray C, Gannon J, Huang H, Lee RT. Thioredoxin-interacting protein controls cardiac hypertrophy through regulation of thioredoxin activity. Circulation 2004; 109: 2581-2586.
38. Hui ST, Andres AM, Miller AK, Spann NJ, Potter DW, Post NM, Chen AZ, Sachithanantham S, Jung DY, Kim JK, Davis RA. Txnip balances metabolic and growth signaling via PTEN disulfide reduction. Proc Natl Acad Sci USA 2008; 105: 3921-3926.
39. Lazaro A, Gallego-Delgado J, Justo P, Esteban V, Osende J, Mezzano S, Ortiz A, Egido J. Long-term blood pressure control prevents oxidative renal injury. Antioxid Redox Signal 2005; 7: 1285-1293.
40. Frey N, Olson EN. Cardiac hypertrophy: The good, the bad, and the ugly. Annu Rev Physiol 2003; 65: 45-79.
41. Neves SR, Ram PT, Iyengar R. G protein pathways. Science 2002; 296: 1636-1639.
42. Yun J, Zuscik MJ, Gonzalez-Cabrera P, McCune DF, Ross SA, Gaivin R, Piascik MT, Perez DM. Gene expression profiling of alpha(1b)-adrenergic receptor-induced cardiac hypertrophy by oligonucleotide arrays. Cardiovasc Res 2003; 57: 443-455.
43. Groves B, Gong Q, Xu Z, Huntsman C, Nguyen C, Li D, Ma D. A specific role of AGS3 in the surface expression of plasma membrane proteins. Proc Natl Acad Sci USA 2007; 104: 18103-18108.
44. Ritchie RH, Marsh JD, Lancaster IND, Diglio CA, Schiebinger RJ. Bradykinin blocks angiotensin II-induced hypertrophy in the presence of endothelial cells. Hypertension 1998; 31: 39-44.
45. Satoh S, Ueda Y, Koyanagi M, Kadokami T, Sugano M, Yoshikawa Y, Makino N. Chronic inhibition of Rho kinase blunts the process of left ventricular hypertrophy leading to cardiac contractile dysfunction in hypertension-induced heart failure. J Mol Cell Cardiol 2003; 35 59-70.
46. Barry SP, Davidson SM, Townsend PA. Molecular regulation of cardiac hypertrophy. Int J Biochem Cell Biol 2008; 40: 2023-2039.
47. Gupte A, Mora S. Activation of the Cbl insulin signaling pathway in cardiac muscle; dysregulation in obesity and diabetes. Biochem Biophys Res Commun 2006; 342: 751-757.
48. Bueno OF, Molkentin JD. Involvement of extracellular signal-regulated kinases 1/2 in cardiac hypertrophy and cell death. Circ Res 2002; 91: 776-781.
49. Nakano S, Kobayashi N, Yoshida K, Ohno T, Matsuoka H. Cardioprotective mechanisms of spironolactone associated with the angiotensin-converting enzyme/epidermal growth factor receptor/extracellular signal-regulated kinases, NAD(P)H oxidase/lectin-like oxidized low-density lipoprotein receptor-1, and Rho-kinase pathways in aldosterone/salt-induced hypertensive rats. Hypertens Res 2005; 28: 925-936.
50. Purcell NH, Wilkins BJ, York A, Saba-El-Leil MK, Meloche S, Robbins J, Molkentin JD. Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo. Proc Natl Acad Sci USA 2007; 104: 14074-14079.
51. Chien KR, Knowlton KU, Zhu H, Chien S. Regulation of cardiac gene expression during myocardial growth and hypertrophy: Molecular studies of an adaptive physiologic response. FASEB J 1991; 5: 3037-3046.
52. Lim DS, Roberts R, Marian AJ. Expression profiling of cardiac genes in human hypertrophic cardiomyopathy: Insight into the pathogenesis of phenotypes. J Am Coll Cardiol 2001; 38: 1175-1180.
53. Micheli L, Leonardi L, Conti F, Buanne P, Canu N, Caruso M, Tirone F. PC4 coactivates MyoD by relieving the histone deacetylase 4-mediated inhibition of myocyte enhancer factor 2C. Mol Cell Biol 2005; 25: 2242-2259.
54. Sussman MA, Welch S, Gude N, Khoury PR, Daniels SR, Kirkpatrick D, Walsh RA, Price RL, Lim HW, Molkentin JD. Pathogenesis of dilated cardiomyopathy: Molecular, structural, and population analyses in tropomodulin-overexpressing transgenic mice. Am J Pathol 1999; 155: 2101-2113.
55. Abe T, Kato M, Miki H, Takenawa T, Endo T. Small GTPase Tc10 and its homologue RhoT induce N-WASP-mediated long process formation and neurite outgrowth. J Cell Sci 2003; 116: 155-168.